O²-vinyl 1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate | 179344-98-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: O²-vinyl 1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate
• 英文别名: (Z)-ethenoxyimino-oxido-pyrrolidin-1-ylazanium
• CAS: 179344-98-0
• 化学式: C₆H₁₁N₃O₂
• 分子量: 157.172
• InChiKey: RJWXCQACZTVGIN-CLFYSBASSA-N

物化性质

• 沸点：
  220.2±23.0 °C(Predicted)
• 密度：
  1.21±0.1 g/cm3(Predicted)
• 闪点：
  14 °C
• 溶解度：
  乙醇

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  53.6
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险品标志：
  F
• 危险类别码：
  R11
• 危险品运输编号：
  UN 1170 3/PG 2
• WGK Germany：
  1
• 安全说明：
  S,S16,S7

反应信息

• 作为产物：
  描述：

  O²-(2-bromoethyl) 1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate 在 sodium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 以423 mg的产率得到O²-vinyl 1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate
  参考文献：
  名称：

  Targeting Nitric Oxide (NO) Delivery in Vivo. Design of a Liver-Selective NO Donor Prodrug That Blocks Tumor Necrosis Factor-α-Induced Apoptosis and Toxicity in the Liver

  摘要：

  We have designed a drug that protects the liver from apoptotic cell death by organ-selective pharmacological generation of the bioregulatory agent, nitric oxide (NO). The discovery strategy involved three steps: identifying a diazeniumdiolate ion (R2N[N(O)NO](-), where R2N = pyrrolidinyl) that spontaneously decomposes to NO with a very short half-life (3 s) at physiological pH; converting this ion to a series of potential prodrug derivatives by covalent attachment of protecting groups that we postulated might be rapidly removed by enzymes prevalent in the liver; and screening the prodrug candidates in vitro and in vivo to select a lead and to confirm the desired activity. Of five cell types examined, only cultured hepatocytes metabolized O-2-vinyl 1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate (V-PYRRO/NO) to NO, triggering cyclic guanosine 3',5'-monophosphate (cGMP) synthesis and protecting the hepatocytes from apoptotic cell death induced by treatment with tumor necrosis factor-alpha (TNF alpha) plus actinomycin D. In vivo, V-PYRRO/NO increased Liver cGMP levels while minimally affecting systemic hemodynamics, protecting rats dosed with TNF alpha plus galactosamine from apoptosis and hepatotoxicity. The results illustrate the potential utility of diazeniumdiolates for targeting NO delivery in vivo and suggest a possible therapeutic strategy for hepatic disorders such as fulminant liver failure.

  DOI：

  10.1021/jm9701031

文献信息

• A GNRH ANTAGONIST FOR USE IN THE TREATMENT OF A WOMEN AFFECTED WITH POLYCYSTIC OVARY SYNDROME
  申请人：Institut National de la Santé et de la Recherche Médicale

  公开号：EP3600373A1

  公开（公告）日：2020-02-05
• ENDOTHELIUM MIMICKING NANOMATRIX
  申请人：Jun Ho-Wook

  公开号：US20100119573A1

  公开（公告）日：2010-05-13

  Disclosed herein are peptide amphiphiles for use in producing a natural endothelium mimicking nanomatrix. The disclosed natural endothelium mimicking nanomatrix can be used to coat medical devices such as vascular stents to promote endothelializaiton and inhibit restenosis and thrombosis. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
• MEDICAL PRODUCT FOR TREATING STENOSIS OF BODY PASSAGES AND FOR PREVENTING THREATENING RESTENOSIS
  申请人：Hoffmann Erika

  公开号：US20100179475A1

  公开（公告）日：2010-07-15

  A method for coating catheter balloons with a defined amount of a pharmacologically active agent, uses a coating device having a volume measuring device for releasing a measurable amount of a coating solution by means of a dispensing device specifically onto the surface of the catheter balloon.
• Balloon Catheter for Treating Stenosis of Body Passages and for Preventing Threatening Restenosis
  申请人：Hoffmann Erika

  公开号：US20110160698A1

  公开（公告）日：2011-06-30

  The present invention is directed to a method for coating catheter balloons with a defined amount of a pharmacologically active agent, wherein the coating method uses a coating device having a volume measuring device for releasing a measurable amount of a coating solution by means of a dispensing device specifically onto the surface of the catheter balloon.
• NO-DONORS FOR THE TREATMENT OF CEREBROVASCULAR VASOSPASMS AFTER BRAIN HEMORRHAGE
  申请人：Ehlert Angelika

  公开号：US20180243314A1

  公开（公告）日：2018-08-30

  The present invention relates to the combined use of NO-donors for the treatment, prevention and/or amelioration of disturbances of the cerebral macro- and microcirculation which disturbances cause cerebrovascular spasms (CVS) and/or malperfusion of brain parenchyma caused by blood vessel and blood flow dysregulation.